Since 2008, downstream purification issues have become progressively more acute problems for biomanufacturers. But that’s begun to change this year, according to results from BioPlan Associates’ 9th ...
Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...
Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...
Downstream processing encompasses the sequence of operations required to isolate, purify and formulate a biopharmaceutical product from crude biological feedstock. Following cell culture or ...
Biopharmaceutical downstream processing requires precise control of multiple unit operations—from chromatography and filtration to viral inactivation—to ensure product quality and therapeutic efficacy ...
Authors: Nick Koumakis and Rut Besseling. Protein aggregation in downstream processing (DSP) is a product-quality concern and major process-performance issue. Aggregate populations can reduce ...
Development of process analytical tools for rapid monitoring of live virus vaccines in manufacturing
In the development of end-to-end large-scale live virus vaccine (LVV) manufacturing, process analytical technology (PAT) tools enable timely monitoring of critical process parameters (CPP) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results